Market Overview - US stock market indices reached historical highs before the Christmas holiday, with the S&P 500 closing at 6932.05 points, up 0.3%, the Dow Jones Industrial Average at 48731.16 points, up 0.6%, and the Nasdaq Composite at 23,613.31 points, up 0.2% [2] - The market is currently experiencing low trading volumes, and investors are watching for the continuation of the "Santa Claus rally" [2] 2026 Market Predictions - Wall Street analysts predict the S&P 500 index will reach between 7100 and 8100 points by 2026, with an average target of 7490 points, indicating an approximately 8% upside from current levels [3] - The anticipated growth is driven by the AI boom and potential interest rate cuts from the Federal Reserve, alongside expected corporate earnings growth [3] - However, concerns about inflation, high valuations, and trade tensions could lead to market corrections [3] Gold and S&P 500 Predictions - Ed Yardeni, a prominent market analyst, forecasts that both the S&P 500 index and gold prices could reach 10,000 points and $10,000 per ounce, respectively, by the end of the decade [4] - His optimistic outlook is based on economic resilience, strong corporate earnings, and productivity gains from the digital revolution and AI [4] Individual Stock Movements - The global precious metals market has rebounded, with silver prices rising 5% to $75.39 per ounce, marking a historical high, and gold reaching $4530 [5] - Mining stocks saw pre-market gains, with notable increases in companies like Coeur Mining (CDE.US) and First Majestic Silver (AG.US) [5] - Biohaven Pharmaceuticals (BHVN.US) shares fell nearly 16% after its experimental depression drug failed to meet mid-stage trial goals [5] - Waymo, Google's autonomous driving division, temporarily suspended services in San Francisco due to flood warnings [6] - Analyst Dan Ives from Wedbush Securities set a target price of $250 for Nvidia (NVDA.US), citing the company's significant potential in the AI sector [6] - XPeng Motors (XPV.US) officially entered the Mauritius market, following its expansion into Qatar and the UAE [7]

Core Viewpoint - Biohaven's stock dropped nearly 13% following the announcement of the failure of its Phase II clinical trial for the antidepressant candidate BHV-7000, leading the company to halt further clinical trials for psychiatric candidates [1][2] Group 1: Clinical Trial Results - The Phase II proof-of-concept study for BHV-7000 did not meet its primary endpoint in treating major depressive disorder [1] - Analysts noted that expectations for the success of the BHV-7000 trial were already low prior to the announcement [1][2] Group 2: Analyst Ratings and Perspectives - Citigroup analyst Samantha Semenkow maintained a "Buy" rating for Biohaven, emphasizing that the disappointing trial data was anticipated [1] - William Blair's Myles Minter rated Biohaven "In Line with the Market," citing increased difficulty in clinical trial execution and enhanced placebo effects as contributing factors [1] - RBC Capital Markets analyst Leonid Timashev suggested that the current setback may be a one-time event, potentially clearing the way for more promising catalysts in 2026 [2] Group 3: Future Focus - Biohaven is shifting its focus to the upcoming topline data from two key studies expected in the first half of 2026, particularly regarding the efficacy of BHV-7000 in treatment-resistant focal epilepsy patients [1][2] - Analysts recommend that investors concentrate on the potential opportunities in the focal epilepsy space, with critical data anticipated in 2026 [2]

Market Overview - US stock market indices reached historical highs before the Christmas holiday, with the S&P 500 closing at 6932.05 points, up 0.3%, the Dow Jones Industrial Average at 48731.16 points, up 0.6%, and the Nasdaq Composite at 23,613.31 points, up 0.2% [2] - The market is currently experiencing low trading volumes, and investors are watching for the continuation of the "Santa Claus rally" [2] 2026 Market Predictions - Wall Street analysts predict the S&P 500 index will reach between 7100 and 8100 points by 2026, with an average target of 7490 points, indicating an approximately 8% upside from current levels [3] - The anticipated growth is driven by the AI boom and potential interest rate cuts from the Federal Reserve, alongside expected corporate earnings growth [3] - However, concerns about inflation, high valuations, and trade tensions could lead to market corrections [3] Gold and S&P 500 Predictions - Ed Yardeni, a prominent market analyst, forecasts that both the S&P 500 index and gold prices could reach 10,000 points and $10,000 per ounce, respectively, by the end of the decade [4] Individual Stock Movements - The global precious metals market has rebounded, with silver prices rising 5% to $75.39 per ounce, marking a historical high, and gold reaching $4530 [5] - Mining stocks saw pre-market gains, with notable increases in companies like Coeur Mining (CDE.US) up 2.72% and First Majestic Silver (AG.US) up 2.67% [5] - Biohaven Pharmaceuticals (BHVN.US) shares fell nearly 16% after its experimental depression drug failed to meet mid-stage trial goals [5] - Waymo, Google's autonomous driving division, temporarily suspended services in San Francisco due to flood warnings [6] - Analyst Dan Ives set a target price of $250 for Nvidia (NVDA.US), citing the company's significant potential in the AI sector [6] - Xpeng Motors (XPV.US) officially entered the Mauritius market, following its expansion into Qatar [6]

Market Overview - U.S. stock futures declined on Friday following a higher close on Wednesday, with major benchmark indices showing a decrease [1][2] - The Dow Jones futures fell by 0.12%, S&P 500 by 0.06%, Nasdaq 100 by 0.06%, and Russell 2000 by 0.27% [2] - The SPDR S&P 500 ETF Trust (SPY) decreased by 0.029% to $690.18, while Invesco QQQ Trust ETF (QQQ) fell by 0.014% to $623.84 in premarket trading [2] Economic Data - U.S. initial jobless claims dropped by 10,000 to 214,000 for the week ending Dec. 20, better than market expectations of 223,000 [1] - The 10-year Treasury bond yield was at 4.15%, and the two-year bond yield was at 3.51% [2] - The CME Group's FedWatch tool indicates an 84.5% probability that the Federal Reserve will keep interest rates unchanged in January [2] Company Highlights - Dynavax Technologies (NASDAQ:DVAX) shares surged by 38.19% following Sanofi's announcement to acquire the vaccines company [5] - Davis Commodities Ltd. (NASDAQ:DTCK) reported revenue of $95 million for the six months ending June 30, a 42.1% increase from $66.9 million a year earlier, leading to a 7.19% rise in its shares [4] - Nvidia Corp. (NASDAQ:NVDA) shares rose by 0.58% after announcing a non-exclusive licensing agreement with AI chip startup Groq [5] - Sobr Safe Inc. (NASDAQ:SOBR) shares dropped by 15.61% after announcing a private placement of 1.29 million shares at $1.55 per share [5][6] - Biohaven Ltd. (NYSE:BHVN) shares fell by 14.06% after its Phase 2 study of BHV-7000 in major depressive disorder failed to meet its primary endpoint [13] Analyst Insights - University of Michigan economist Justin Wolfers criticized the media's focus on record stock numbers, stating that U.S. markets are up 18% but lag behind global markets, which have risen by 30% [9][10] - Wolfers highlighted a disconnect between GDP growth of over 4% and a more modest Gross Domestic Income (GDI) growth of 2.4%, suggesting potential job creation stagnation [10]

分组1 - Davis Commodities Ltd reported a revenue of $95 million for the first half of the fiscal year, marking a 42.1% increase from $66.9 million in the same period last year [1] - The company's shares rose by 5.6% to $0.25 in pre-market trading following the financial results announcement [1] 分组2 - Picocela Inc experienced a significant surge of 50.4% to $0.35 in pre-market trading after a previous decline of over 35% [6] - X3 Holdings Co Ltd saw an increase of 30.3% to $0.21 in pre-market trading [6] - Sidus Space Inc rose by 28.2% to $2.82 after announcing the closing of a public offering [6] - Multi Ways Holdings Ltd shares jumped 22.2% to $0.43 after reporting a year-over-year increase in H1 EPS results [6] - Northann Corp gained 19.7% to $0.32 after engaging Linkun Investment and Lu Wang for strategic planning advisory services [6] - Millennium Group International Holdings Ltd increased by 15.8% to $1.54 in pre-market trading [6] - K Wave Media Ltd rose 13.4% to $0.46 after announcing plans to acquire a controlling stake in Hansol Inticube [6] - AlphaTON Capital Corp increased by 11.1% to $0.72 after a previous decline [6] - Sigma Lithium Corp gained 8.6% to $14.67 in pre-market trading [6]

Core Viewpoint - Biohaven's experimental depression drug failed to meet primary goals in mid-stage trials, leading to a nearly 14% pre-market drop in stock price to $9.31 [1] Group 1: Clinical Trial Results - The drug BHV-7000 did not show significant improvement in depressive symptoms compared to a placebo in a six-week trial involving patients with severe depression [1] - The company considers the subgroup analysis for depression as "hypothetical exploration" and does not plan to conduct further psychiatric clinical trials [1] Group 2: Strategic Focus - Biohaven intends to concentrate resources on key priority areas such as immunology, obesity, and epilepsy, aiming for a shift in focus by 2026 [1]

Group 1 - Nvidia Corp. shares increased to $190.16 in overnight trading after announcing a non-exclusive licensing agreement with AI chip startup Groq, which covers its inference technology [1][1][1] - Dynavax Technologies Corp. shares surged 38.2% to close at $15.38 following Sanofi's announcement to acquire the vaccines company [1][1][1] - Sobr Safe Inc. shares jumped 82.3% to close at $2.37 after announcing definitive agreements to issue 1.29 million shares of common stock at $1.55 per share in a private placement [1][1][1] Group 2 - Davis Commodities Ltd. reported revenue of $95 million for the six months ending June 30, a 42.1% increase from $66.9 million a year earlier, but shares fell 8.9% to close at $0.24 [1][1][1] - Biohaven Ltd. disclosed that its Phase 2 proof-of-concept study of BHV-7000 in major depressive disorder did not meet its primary endpoint, with shares gaining 3% to close at $10.81 [1][1][1]

Group 1 - Biohaven's experimental depression drug failed to meet primary endpoints in a mid-stage trial, contributing to a stock price drop of 16% in after-hours trading and an overall decline of over 70% this year [1] - The company previously faced a clinical trial failure in March and a rejection from U.S. regulators for its drug Troriluzole, intended for treating a rare neurodegenerative disease [1] - In a six-week trial for patients with major depressive disorder, Biohaven's drug BHV-7000 did not show significant differences in depression symptom reduction compared to a placebo [1] Group 2 - Biohaven plans to focus resources on key priority areas such as immunology, obesity, and epilepsy by 2026, and will not pursue additional psychiatric clinical trials [1] - Analyst Leonid Tsymashev noted that the trial failure was not surprising given the limited clinical efficacy data and the challenges associated with major depressive disorder [1] - Following the FDA's rejection of Troriluzole, Biohaven announced a plan to cut annual direct R&D spending by approximately 60% [2]

Core Insights - Biohaven Ltd. reported results from a Phase 2 proof-of-concept study for BHV-7000 aimed at treating major depressive disorder (MDD), which did not meet its primary endpoint of reducing depressive symptoms compared to placebo [1] - Some positive trends were observed in specific subgroups, particularly those with more severe depression, although the overall efficacy was not supported [1] - The safety profile of BHV-7000 was favorable, with adverse events primarily mild to moderate, and the most common adverse events being headache (10.7% in BHV-7000 vs. 9.9% in placebo) and nausea (4.2% in BHV-7000 vs. 5.6% in placebo) [1] - The company plans to focus its resources on key therapeutic areas such as immunology, obesity, and epilepsy, rather than pursuing further psychiatric clinical trials for BHV-7000 [1] Company Overview - Biohaven is a biopharmaceutical company dedicated to developing life-changing therapies across various therapeutic areas, including immunology, obesity, neuroscience, and oncology [3] - The company is advancing its innovative portfolio, which includes programs targeting Kv7 ion channels for epilepsy and mood disorders, as well as extracellular protein degraders for immunological diseases [3] - Biohaven's management will present updates on its clinical programs at the upcoming J.P. Morgan Healthcare Conference in January 2026, highlighting ongoing studies and new developments [2][5]

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 Hangzhou Highlightll Pharmaceutical Co., Ltd. 杭州高光製藥股份有限公司 （於中華人民共和國成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監 會」）的要求而刊發，僅用作提供資訊予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件， 即代表 閣下知悉、接納並向杭州高光製藥股份有限公司（「本公司」）、其聯席保薦人、整體協 調人、顧問或包銷團成員表示同意： 於本公司招股章程根據香港法例第32章公司（清盤及雜項條文）條例送呈香港公司註冊處處長登 記前，不會向香港公眾人士提出要約或邀請。倘在適當時候向香港公眾人士提出要約或邀請， 有意投資者務請僅依據於香港公司註冊處處長登記的本公司招股章程作出投資決定。該文件的 文本將於發售期內向公眾人士刊發 ...